Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets

Breast Cancer Research and Treatment

Volumn 155, Issue 1, 2016, Pages 65-75

  Nakagawa, Saki ^a,b   Miki, Yasuhiro ^a   Miyashita, Minoru ^a   Hata, Shuko ^a   Takahashi, Yayoi ^b   Rai, Yoshiaki ^c   Sagara, Yasuaki ^c   Ohi, Yasuyo ^c   Hirakawa, Hisashi ^d   Tamaki, Kentaro ^a   Ishida, Takanori ^a   Watanabe, Mika ^b   Suzuki, Takashi ^a   Ohuchi, Noriaki ^a   Sasano, Hironobu ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c SAGARA HOSPITAL   (Japan)

^d TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Cancer associated fibroblasts; Insulin like growth factor 1; Invasive lobular carcinoma; Microvessel density; Nestin; Vasohibin 1 positive ratio

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; CD34 ANTIGEN; CELL MARKER; KI 67 ANTIGEN; NESTIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASOHIBIN 1; ACTIN; ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; VASH1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER STAGING; CAPILLARY DENSITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRATUMORAL MICROVESSEL MATURATION; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); ONCOLOGICAL PARAMETERS; PERICYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; CARCINOMA, LOBULAR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR VOLUME; VERY ELDERLY;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ANTIGENS, CD34; BIOMARKERS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NESTIN; RECEPTOR, IGF TYPE 1; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84953346778     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3668-9     Document Type: Article

References (48)

1. Fisher ER, Gregorio RM et al (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36(1):1–85
2. Arpino G, Bardou VJ et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156
3. Sastre-Garau X, Jouve M et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77(1):113–120
4. Katz A, Saad ED et al (2007) Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 8:55–62
5. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
6. Korhonen T, Kuukasjärvi T et al (2013) The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast 22:1119–1124
7. Wasif N, Maggard MA et al (2010) Invasive lobular versus ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 17:1862–1869
8. Cleton-Jansen AM (2001) E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4:5–8
9. Mersin H, Yildirim E, Gulben K, Berberoglu U (2003) Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 29:390–395
10. Truin W, Vugts G et al (2015) Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. doi:10.1245/s10434-015-4603-3
11. Coradini D et al (2002) Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 87(10):1105–1111
12. Le Gal M, Ollivier L, Asselain B et al (1992) Mammographic features of 455 invasive lobular carcinomas. Radiology 185:705–708
13. Wellings SR, Jensen HM (1975) An atlas of sub gross pathology of human breast with special reference to possible cancerous lesions. J Natl Cancer Inst 55:231–273
14. Ohuchi N, Abe R, Kasai M (1984) Possible cancerous change of intraductal papillomas of the breast: a 3-D reconstruction of 25 cases. Cancer 54:605–611
15. Turashvili G, Bouchal J, Kolar Z et al (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55. doi:10.1186/1471-2407-7-55
16. Miyashita M, Sasano H, Tamaki K, Ohuchi N et al (2014) Tumor-infiltrating CD8+ and FOXP3+ in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Tr. 148(3):525–534. doi:10.1007/s10549-014-3197-y
17. Ali HR, Provenzano E, Caldas C et al (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 25:1536–1543. doi:10.1093/annonc/mdu191
18. Mao Y, Keller ET (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32:303–315. doi:10.1007/s10555-012-9415-3
19. Kalluri R et al (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392–401
20. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters M-J, Sonke GS, Berry DA, van‘t Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators, Laura J (2012) Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-012-2233-z
21. Uzzan B, Nicolas P, Cucherat M, Perret G-Y (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64:2941–2955
22. Sato Y (2013) The vasohibin family: a novel family for angiogenesis regulation. J Biochem 153(1):5–11. doi:10.1093/jb/mvs128
23. Tamaki K, Moriya T, Sato Y, Ishida T, Ohuchi N, Sasano H et al (2009) Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci 100(1):88–94. doi:10.1111/j.1349-7006.2008.01015.x
24. Matsuda Y, Hagio M, Ishikawa T (2013) Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol 19(1):42–48. doi:10.3748/wjg.v19.i1.42
25. Liu C, Chen B, Zhu J, Zhang R, Yao F, Jin F, Huimian X, Ping L (2010) Clinical implications for nestin protein expression in breast cancer. Cancer Sci 10:815–819. doi:10.1111/j.1349-7006.2009.01422.x
26. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223. doi:10.1093/annonc/mdt303
27. Sobin LH, Wittekind C (2011) TNM Classification of malignant tumours, 7th edn. Wiley, Hoboken, pp 131–141
28. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AHS, Ellis IO (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Tr 111(1):121–127. doi:10.1007/s10549-007-9768-4
29. Vered M, Dobriyan A, Dayan D, Yahalom R, Talmi YP, Bedrin L, Barshack I, Taicher S (2010) Tumor-host histopathologic variables, stromal myofibroblasts and risk score, are significantly associated with recurrent disease in tongue cancer. Cancer Sci 101:274–280. doi:10.1111/j.1349-7006.2009.01357.x
30. Cheng Y, Wang K, Ma W, Zhang X, Song Y, Wang J, Wang N, Song Q, Cao F, Tan B, Jinming Y (2015) Cancer-associated fibroblasts are associated with poor prognosis in esophageal squamous cell carcinoma after surgery. Int J Clin Exp Med 8(2):1896–1903
31. Li Z-J, Ying X-J, Chen H-L, Ye P-J, Chen Z-L, Li G, Jiang H-F, Liu S-Z Zhou (2013) Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer. World J Gastroenterol 19(43):7788–7794. doi:10.3748/wjg.v19.i43.7788
32. Pilichowska M, Kimura N, Fujikawa H, Nagura H (1997) Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma. Modern Pathol. 10(10):969–975
33. Aaltonen KE, Rosendahl AH, Olsson H, Malmström P, Hartman L, Fernö M (2014) Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. BMC Cancer 14:794
34. Hu M, Yao J, Carroll DK et al (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13(5):394–406. doi:10.1016/j.ccr.2008.03.007
35. Ostman A, Augsten M (2009) Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Curr Opin Genet Dev 19(1):67–73. doi:10.1016/j.gde.2009.01.003
36. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig 116(7):1955–1962. doi:10.1172/JCI26532
37. Bonkowski D (2011) The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS. 8:8
38. Krüger K, Stefansson IM, Collett K, Arnes JB, Aas T, Akslen LA (2013) Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. The Breast 22:282–288. doi:10.1016/j.breast.2012.07.008
39. Yazdania S, Miki Y, Tamaki K, Ono K, Suzuki T, Sato Y, Sasano H (2013) Proliferation and maturation of intratumoral blood vessels in non–small cell lung cancer. Hum Pathol 44:1586–1596. doi:10.1016/j.humpath.2013.01.004
40. Raza A, Franklin MJ, Dudek AZ (2010) Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85:593–598. doi:10.1002/ajh.21745
41. Bhati R, Patterson C, Klauber-DeMore N et al (2008) Molecular characterization of human breast tumor vascular cells. Am J Pathol 172(5):1381–1390. doi:10.2353/ajpath.2008.070988
42. Christopoulos PF, Msaouel P, Koutsilieris M (2015) The role of the insulin-like growth factor-1 system in breast cancer. Molecular Cancer 14:43. doi:10.1186/s12943-015-0291-7
43. Bertucci F, Orsetti B, Theillet C et al (2008) Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27(40):5359–5372. doi:10.1038/onc.2008.158
44. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY et al (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 63:7167–7175
45. Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K (2006) The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Tr 99:275–288. doi:10.1007/s10549-006-9215-y
46. Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S, Reinecke M (2002) IGF-1 in human breast cancer: low differentiation stage is associated with decreased IGF-1 content. European J of Endocrinopathy 146:813–821
47. Law JH, Habibi G, Dunn SE et al (2008) Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238–10246. doi:10.1158/0008-5472.CAN-08-2755
48. Gil EMC (2014) Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treatment Reviews 40:862–871. doi:10.1016/j.ctrv.2014.03.004